<p><strong>General</strong>: Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either:</p>

<ul>
	<li>1200 mg administered by IV infusion every 3 weeks or</li>
	<li>1680 mg administered by IV infusion every 4 weeks.</li>
</ul>

<p><strong>1L cisplatin-ineligible mUC</strong>: Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test</p>